ACY-241

DRUG4 trials

Sponsors

Celgene

Conditions

Advanced Solid TumorsMalignant MelanomaMultiple MyelomaNon Small Cell Lung Cancer

Phase 1

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

TerminatedNCT02400242

CelgeneMultiple Myeloma

Start: 2015-05-07End: 2024-06-03Updated: 2024-07-09

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

CompletedNCT02551185

CelgeneAdvanced Solid Tumors

Start: 2015-12-22End: 2019-10-04Updated: 2020-02-26

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

TerminatedNCT02635061

CelgeneNon Small Cell Lung Cancer

Start: 2016-08-25End: 2024-01-22Updated: 2024-05-07

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

CompletedNCT02935790

CelgeneMalignant Melanoma

Start: 2016-09-30End: 2017-04-07Updated: 2017-08-24

Related Papers

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Frontiers in Oncology2022-01-0714 citations

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Frontiers in Oncology2021-09-0641 citations

Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-205 citations

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

Journal of Clinical Oncology2018-05-207 citations

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Blood2016-12-0220 citations

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Blood2015-12-0321 citations

Abstract A187: Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Molecular Cancer Therapeutics2015-12-012 citations